Pulmonary hypertension life expectancy and prognosis can vary broadly, but have improved in the era of modern treatment.

Early diagnosis of pulmonary arterial hypertension improves five-year survival by 42%, compared with delayed diagnosis, a ...

SAN ANTONIO — Patients given higher doses of oral and subcutaneous treprostinil experience a significantly longer time before their first pulmonary arterial hypertension (PAH)-related and all-cause ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR ™ (sotatercept-csrk) compared to ...

Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA pressure ...

Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) prevalence is higher among Medicaid beneficiaries, with significant racial and ethnic disparities, particularly affecting Black ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

KIDS. I WAS PLAYING BASKETBALL AND I WAS BICYCLING AND DOING ALL THE THINGS I WANTED TO DO WHEN SUDDENLY I COULDN’T. DIAGNOSED WITH PULMONARY ARTERIAL HYPERTENSION OR PAH MIKE BENNETT LEARNED HE WAS ...

Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...

WINREVAIR significantly reduced the risk of major morbidity and mortality events, the primary endpoint, in adults with PAH (Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality ...